%0 Journal Article
%T Ocriplasmin for Vitreoretinal Diseases
%A Irena Tsui
%A Carolyn K. Pan
%A Ehsan Rahimy
%A Steven D. Schwartz
%J Journal of Biomedicine and Biotechnology
%D 2012
%I Hindawi Publishing Corporation
%R 10.1155/2012/354979
%X Fibronectin and laminin are clinically relevant plasmin receptors in the eye. Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication. A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway. The results are promising and may impact patient care.
%U http://www.hindawi.com/journals/biomed/2012/354979/